Table of Contents
About This Report Beginning with the recent approval of Gilenya (Novartis; fingolimod), MS patients are experiencing the arrival of more effective and less invasive treatment options after numerous years of limited therapeutic options. As competition intensifies, the need for less invasive modes of administration will be met and new drugs will have to compete on other factors, such as efficacy. What's Included in This Rep...More »
The Largest Collection of Market Research Reports
From +200,000 authoritative sources
Talk to Robyn
00 1 718 213 49 04
"Analytical Tool - Hematological Cancers" offers a unique tool for analyzing the vast amount of strategic possibilities that have emerged in R&D and business development in hematological cancers. It is ...
Actonel (Osteoporosis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, ?Actonel (Osteoporosis) - Forecast and Market Analysis to 2022?. ...
REPORT SCOPE INTRODUCTION REASONS FOR DOING THE STUDY The spread of human immunodeficiency virus (HIV), hepatitis B and C, evolving influenza strains and antibiotic-resistant organisms have put healthcare ...
... Guidelines say People with diabetes and hypertension should be treated to a systolic blood pressure goal of 140 mmhg. Lower systolic targets (such as ...
... A diagnosed mental health condition as per the icd-10 categories (children do not require a mental health diagnosis, however, must be demonstrating symptoms that indicate they are at significant risk ...
Company Profiles10 Companies
Reportlinker.com © Copyright 2013. All rights reserved.